Reactions 1401 - 12 May 2012

SAntineoplastics

Long-term respiratory impairment: 9 case reportsA study identified six men and three women aged

26–52 years who had developed long-term respiratoryimpairment after past treatment with BEACOPP or ABVDchemotherapy [routes not stated] for Hodgkin’slymphoma.

At least 3 years earlier, the patients had received either a6-cycle BEACOPP regimen (bleomycin 10 mg/m2,vincristine 1.4 mg/m2, procarbazine 700 mg/m2,prednisone 280 mg/m2, etoposide 300 mg/m2 or600 mg/m2, doxorubicin 25 mg/m2 or 35 mg/m2, andcyclophosphamide 650 mg/m2 or 1250 mg/m2) or an ABVDregimen (bleomycin 10 mg/m2, vinblastine 6 g/m2,doxorubicin 25 mg/m2 and dacarbazine 375 mg/m2 withdexamethasone 20mg every 14 days); their cumulativebleomycin doses were 60–120 mg/m2 [number of ABVDcycles not stated]. Three of the patients had functionaldyspnoea, and investigations revealed diffusing capacity ofcarbon monoxide (DLCO) results of 46–70% [times toonset of reactions, treatments and outcomes not stated].Avivi I, et al. Low incidence of long-term respiratory impairment in Hodgkinlymphoma survivors. Annals of Hematology 91: 215-21, No. 2, Feb 2012.Available from: URL: http://www.springerlink.com/content/0939-5555/91/2/ -Israel 803069855

1

Reactions 12 May 2012 No. 14010114-9954/10/1401-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved